Paid Clinical Trials Alaska
Discover 119 paid clinical trials in Alaska. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04071457
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lenalidomide
Daratumumab/rHuPH20
Nivolumab, Ipilimumab, CabozantinibTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography Test
Sacituzumab vs. TreatmentA Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06459180
Conditions
Cervical Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab Tirumotecan
Pemetrexed
Tisotumab Vedotin
Topotecan
Vinorelbine
Glofitamab & Polatuzumab VedotinAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06047080
Conditions
Large B-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Glofitamab
Polatuzumab vedotin
Rituximab
Cyclophosphamide
Doxorubicin
Paclitaxel & IpatasertibStudy of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05554380
Conditions
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy Procedure
Biospecimen Collection
Computed Tomography
Ipatasertib
Magnetic Resonance Imaging
Golcadomide & R-CHOPStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Sponsor:
Celgene
Location:
Code:
NCT06356129
Conditions
Large B-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Golcadomide
Placebo
Rituximab
Cyclophosphamide
Doxorubicin
AvacopanA Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Sponsor:
Amgen
Location:
Code:
NCT06072482
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Avacopan
Placebo
Standard of Care
Radiation Therapy with AtezolizumabStudy of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04310020
Conditions
Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Biospecimen Collection
Computed Tomography
Hypofractionated Radiation Therapy
Magnetic Resonance Imaging
Immunotherapy with ChemotherapyTesting the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04267848
Conditions
Lung Non-Small Cell Carcinoma
Lung Non-Small Cell Squamous Carcinoma
Lung Non-Squamous Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Carboplatin
Cisplatin
Computed Tomography
Echocardiography Test